Can a cancer biopsy predict who responds to a new immunotherapy?
NCT ID NCT07748364
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug glofitamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Glofitamab is a type of immunotherapy that helps the body's T-cells attack cancer cells. The study uses tumor biopsies taken before and during treatment to see if changes in the tumor can help predict how well the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab (Columvi), a bispecific antibody that helps T-cells attack lymphoma cells
- What this could lead to
- If successful, this could lead to a more personalized approach for treating aggressive B-cell lymphomas, potentially improving outcomes for patients who have relapsed.
- What could go wrong
- This is a small, early-phase trial, so results may not apply broadly. The treatment may cause side effects, and the biomarker approach is still experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- New drug cocktail aims to tackle tough lymphoma
- New drug combo shows promise for Tough-to-Treat lymphoma
- New hope for tough lymphoma: experimental drug shows promise